The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance ...

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

Data from 2 studies, LIGHTHOUSE and SPOTLIGHT, have shown the benefit of flotufolastat F 18 injection as a radiohybrid PSMA-targeted PET imaging agent in prostate cancer. The agent has now been added ...

Early-stage prostate cancer is very treatable with surgery and radiation therapy. Once the cancer spreads, it becomes harder to stop. Late-stage prostate cancer treatments like chemotherapy and ...

The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...

Even when diagnosed at an advanced stage, most prostate cancers respond well to treatment. The first line of treatment is often hormone therapy, which is very good at slowing or stopping the cancer — ...

For patients with oligometastatic cancers, particularly kidney or prostate, stereotactic body radiotherapy may frequently ...

For more than 80 years, men have been told that testosterone helps prostate cancer grow. But a very different picture has emerged over the past two decades.

A PSA of 127 indicated a high probability of prostate cancer, leading to immediate Lupron ADT therapy and radiation treatment ...

Endocrine therapy is a way of treating conditions such as cancer using hormones. Also known as hormone therapy, it involves adjusting the levels of certain hormones, such as testosterone, estrogen, ...